Andrx once-daily fexofenadine under development with Sepracor -- SEC registration.

Executive Summary

ANDRX ONCE-DAILY FEXOFENADINE WILL BE FIRST BRANDED PRODUCT, the company indicates in a recent registration statement filed with the Securities & Exchange Commission. Under an April 1996 agreement with Sepracor, Andrx will develop a once-daily formulation of fexofenadine (terfenadine carboxylate) and will receive fees and royalties from eventual sales or licensing of the antihistamine. Under the agreement, Sepracor has responsibility for obtaining FDA approval, manufacturing and marketing the once-daily fexofenadine.